NasdaqCM - Delayed Quote USD

Sunshine Biopharma, Inc. (SBFM)

0.6951 -0.0599 (-7.93%)
At close: May 28 at 4:00 PM EDT
0.7000 +0.00 (+0.70%)
After hours: May 28 at 7:58 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Steve N. Slilaty Ph.D. CEO, President & Chairman 640k -- 1952
Mr. Camille Sebaaly CFO & Secretary 695k -- 1959
Dr. Abderrazzak Merzouki Chief Science Officer & Director 340k -- 1964
Mr. Marc Beaudoin Chief Operating Officer -- -- 1967
Mr. Malek Chamoun Chief Development Officer -- -- 1985
Mr. Robert G. Ferreira President of Sunshine Bio Investments Inc -- -- 1962

Sunshine Biopharma, Inc.

1177 Avenue of the Americas
5th floor
New York, NY 10036
United States
332 216 1147 https://sunshinebiopharma.com
Sector: 
Healthcare
Full Time Employees: 
44

Description

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

Corporate Governance

Sunshine Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 9, 2024 at 12:30 PM UTC - August 13, 2024 at 12:30 PM UTC

Sunshine Biopharma, Inc. Earnings Date

Recent Events

May 22, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 20, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 15, 2024 at 12:00 AM UTC

NT 10-Q: Periodic Financial Reports

May 8, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 23, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 1, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 28, 2024 at 12:00 AM UTC

10-K: Periodic Financial Reports

March 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 5, 2024 at 12:00 AM UTC

DEF 14C: Proxy Statements

Related Tickers